Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01345864 · ClinicalTrials.gov registry record · Phase 1
Assessment Of The Effects Of Single Doses Of An Investigational Drug, Given Alone Or With Donepezil, On Scopolamine-Induced Changes In Memory And Learning In Healthy Adults
A Phase 1 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 88
- Enrollment target
NCT01345864: Clinical Trial Phase 1 study, sponsored by Pfizer.
NCT01345864 is a Phase 1 study that was terminated before completion, run by Pfizer. The registered enrollment target is 88 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (47% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01345864, a Phase 1 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 88 participants
- Enrollment target
Study Summary
This study is designed to look at the potential for an investigational drug (PF-04995274, under development by Pfizer, Inc. as a potential treatment for Alzheimer's disease) to reverse changes in memory and learning/problem solving skills caused by co-administration of a marketed drug called scopolamine. Scopolamine is known to cause temporary changes in memory and learning/problem solving skills that are similar to those seen in people with alzheimer's disease(AD).
Interventions
- DRUG Scopolamine + Donepezil Placebo + PF-04995274 Placebo
- DRUG Scopolamine + Donepezil 5 mg + PF-04995274 Placebo
- DRUG Scopolamine + Donepezil 10mg + PF-04995274 Placebo
- DRUG Scopolamine + Donepezil Placebo + PF-04995274 0.25 mg
- DRUG Scopolamine + Donepezil Placebo + PF-04995274 15 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2011-05 |
| Est. Completion | 2011-08 |
| Phase | Phase 1 |
Why NCT01345864 stopped before completion
NCT01345864 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 88 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (47% higher).
The record links to 0 conditions, and to 5 interventions - of which Scopolamine + Donepezil Placebo + PF-04995274 Placebo is the first listed.
NCT01345864 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01345864 about?
NCT01345864 is a clinical study titled "Assessment Of The Effects Of Single Doses Of An Investigational Drug, Given Alone Or With Donepezil, On Scopolamine-Induced Changes In Memory And Learning In Healthy Adults". This study is designed to look at the potential for an investigational drug (PF-04995274, under development by Pfizer, Inc. as a potential treatment for Alzheimer's disease) to reverse changes in memory and learning/problem solving skills caused by co-administration of a marketed drug called scopola...
What is the current status of trial NCT01345864?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 88 participants. The study started on 2011-05. Estimated completion is 2011-08.
What interventions are being tested in trial NCT01345864?
The interventions under investigation include: Scopolamine + Donepezil Placebo + PF-04995274 Placebo (DRUG), Scopolamine + Donepezil 5 mg + PF-04995274 Placebo (DRUG), Scopolamine + Donepezil 10mg + PF-04995274 Placebo (DRUG), Scopolamine + Donepezil Placebo + PF-04995274 0.25 mg (DRUG), Scopolamine + Donepezil Placebo + PF-04995274 15 mg (DRUG).
Who is sponsoring clinical trial NCT01345864?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01345864's enrollment target sits among peer trials
88 650th of 2000 higher than 1,350 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03843463 · 88 participants · Phase 2
Escitalopram and Language Intervention for Subacute Aphasia
- NCT04066348 · 88 participants · Phase 2
TNF-α Treatment of Blast-Induced Tinnitus
- NCT04331704 · 88 participants · Phase 4
ANCHORS Alcohol & Sexual Health Study: UH3 Project
- NCT04536103 · 88 participants
Multi-Vendor Multi-Site Novel Accelerated MRI Relaxometry
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia